Exon skipping therapy for Duchenne muscular dystrophy — the antisense oligonucleotide (ASO) approach using synthetic nucleic acid molecules that bind pre-mRNA splicing signals to cause targeted exon exclusion during RNA processing, converting the out-of-frame DMD gene mutations causing Duchenne muscular dystrophy into in-frame mutations producing a shorter but partially functional truncated dystrophin protein similar to the milder Becker muscular dystrophy — representing the most commercially advanced precision genetic therapy approach within the Duchenne Muscular Dystrophy Treatment Market, with multiple FDA-approved exon skipping products establishing the regulatory template for this therapeutic class.

DMD genetics and the exon skipping rationale — the genetic architecture of DMD (mutations in the DMD gene on the X chromosome, primarily large deletions disrupting the reading frame and preventing production of functional dystrophin, with approximately forty-three percent of DMD patients amenable to exon 51 skipping, thirteen percent to exon 53 skipping, and eight percent to exon 45 skipping) creating distinct patient subpopulations addressable by exon-specific ASO therapies. Sarepta Therapeutics' eteplirsen (Exondys 51 — FDA accelerated approval 2016, first approved exon skipping DMD therapy) establishing the FDA regulatory pathway for exon skipping despite ongoing controversy about the clinical meaningfulness of its dystrophin restoration endpoint in the accelerated approval setting.

The exon skipping competitive landscape — Sarepta's DMD franchise expansion — Sarepta Therapeutics dominating the exon skipping market with eteplirsen (exon 51), golodirsen (Vyondys 53 — exon 53, FDA approved 2019), and casimersen (Amondys 45 — exon 45, FDA approved 2021) covering the three largest DMD mutation subpopulations addressable by exon skipping. NS Pharma (subsidiary of Nippon Shinyaku) competing in the exon 53 market with viltolarsen (Viltepso — FDA approved 2020), creating competition in the exon 53 patient subpopulation. Each product requiring specialized chemistry (phosphorodiamidate morpholino oligomers — PMO — for Sarepta; 2'-O-methyl phosphorothioate for NS Pharma) and administered by weekly IV or subcutaneous injection.

Delandistrogene moxeparvovec — the micro-dystrophin gene therapy redefining treatment ambition — Sarepta Therapeutics' Elevidys (SRP-9001, approved FDA June 2023 via accelerated approval for ambulatory DMD patients 4–5 years old) delivering an engineered micro-dystrophin gene via AAV rh74 vector in a single IV infusion, providing potentially durable dystrophin restoration across the full body musculature — a fundamentally more ambitious treatment paradigm than weekly ASO administration. The EMBARK Phase III trial's mixed results (primary functional endpoint not met in overall population, but gene expression and prespecified subgroup analyses showing benefit) creating the clinical evidence ambiguity that has characterized the DMD gene therapy regulatory journey and motivated ongoing outcome data collection.

Do you think micro-dystrophin gene therapy will eventually become the definitive treatment for Duchenne muscular dystrophy, replacing the ongoing burden of weekly exon skipping injections, or will safety concerns, clinical efficacy limitations, and the extraordinarily high cost of gene therapy maintain exon skipping as a primary long-term treatment modality for most DMD patients?

FAQ

What exon skipping therapies are currently FDA-approved for DMD and which patient mutations are eligible? FDA-approved DMD exon skipping therapy guide: eteplirsen (Exondys 51, Sarepta Therapeutics): approved September 2016 (accelerated approval); targets exon 51; mutation eligibility: DMD patients with confirmed deletion mutations amenable to exon 51 skipping (~43% of DMD); dose: 30mg/kg IV weekly; chemistry: PMO (phosphorodiamidate morpholino oligomer); golodirsen (Vyondys 53, Sarepta Therapeutics): approved December 2019 (accelerated approval); targets exon 53; mutation eligibility: ~8% of DMD patients; dose: 30mg/kg IV weekly; PMO chemistry; casimersen (Amondys 45, Sarepta Therapeutics): approved February 2021 (accelerated approval); targets exon 45; mutation eligibility: ~8% of DMD patients; dose: 30mg/kg IV weekly; PMO chemistry; viltolarsen (Viltepso, NS Pharma): approved August 2020; targets exon 53; mutation eligibility: same as golodirsen (~8%); dose: 80mg/kg IV weekly; 2'-O-methyl phosphorothioate chemistry; mutation testing: MLPA (Multiplex Ligation-dependent Probe Amplification) or next-generation sequencing to determine DMD mutation type and exon skipping amenability; clinical utility: accelerated approval based on dystrophin protein increase as surrogate endpoint; confirmatory trial data pending for each product; cost: approximately $300,000–$500,000 per year per patient; access: manufacturer patient assistance programs; state Medicaid coverage variable; prior authorization required by most payers.

What standard of care and supportive treatments are used alongside emerging DMD therapies? DMD comprehensive standard of care: corticosteroids: deflazacort (Emflaza — FDA approved 2017 for DMD) and prednisone/prednisolone — backbone of DMD standard of care; mechanism: anti-inflammatory, stabilizing muscle membrane; slowing disease progression; maintaining ambulation on average 1.5–2 years longer; vamorolone (Agamree — FDA approved 2023): novel dissociative steroidal anti-inflammatory; reduced side effect profile versus deflazacort in VISION-DMD trial; less growth restriction, fewer bone density effects; cardiac management: cardiology monitoring from age six; ACE inhibitor and/or beta-blocker for cardiomyopathy (typically emerging second decade); ICD consideration for arrhythmia; respiratory support: forced vital capacity monitoring; BiPAP non-invasive ventilation for nocturnal hypoventilation (typically second decade); cough assist devices; tracheostomy consideration; physical therapy: stretching and joint range of motion preservation; orthoses (ankle-foot orthosis — AFO) for ambulation preservation; power wheelchair for mobility after ambulation loss; nutritional support: swallowing assessment; high-calorie nutrition support; constipation management; bone health: calcium, vitamin D, bisphosphonate for steroid-induced osteoporosis; fracture prevention; psychosocial: neuropsychological assessment (cognitive and behavioral challenges in DMD); school accommodation support; mental health support for patient and family; multidisciplinary care model: neuromuscular center with neurologist, cardiologist, pulmonologist, physical therapist, occupational therapist, speech therapist, nutritionist, social worker, genetic counselor.